Attana AB (publ) (NGM:ATANA)

Market Cap	5.16M -83.2%
Revenue (ttm)	1.17M -61.4%
Net Income	-9.88M
EPS	-0.01
Shares Out	2.58B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,383,764
Open	n/a
Previous Close	0.0030
Day's Range	n/a
52-Week Range	0.0020 - 0.0170
Beta	0.85
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 29, 2026

About Attana AB

Attana AB (publ) operates as a life science and diagnostics company in Sweden. The company offers contract research services; Attana Cell 250, an analytical instrument; biosensor chips, reagents, and buffers; and Attana Virus Analytics, a diagnostic application. Its products and services are used in antibody development, vaccine development, cell-based assays, immunogenicity studies, infectious diseases, biological interaction analysis, drug discovery and development, and translational research applications. The company was founded in 2002 and ...

• Industry: Commercial Physical and Biological Research
• Founded: 2002
• Employees: 6
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ATANA

Financial Performance

In 2025, Attana AB's revenue was 2.47 million, a decrease of -39.74% compared to the previous year's 4.10 million. Losses were -10.50 million, -17.80% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 2, 2026

Data Sources Report a data error